Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 6/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | MMP14 | P50281 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5076581 | 1.00 | HDAC3 (0.57) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL16860742 | 0.91 | L3MBTL1 (0.69) | SLC1A1LTA4HL3MBTL1LMNAPKM | |
| SCHEMBL16860729 | 0.90 | LMNA (0.63) | SLC1A1LTA4HL3MBTL1LMNAPKM | |
| SCHEMBL14381163 | 0.90 | LTA4H (0.59) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL16860743 | 0.89 | LMNA (0.62) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL23950311 | 0.88 | SLC7A5 (0.51) | SLC1A1LTA4HF13A1PLAAT5PLAAT4 | |
| SCHEMBL31540123 | 0.88 | SLC7A5 (0.51) | SLC1A1LTA4HF13A1PLAAT5PLAAT4 | |
| SCHEMBL31369915 | 0.87 | CA1 (0.49) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL19051470 | 0.87 | CA1 (0.49) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL8984747 | 0.84 | SLC1A3 (0.56) | HDAC3HDAC1HDAC2HDAC10HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976873-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-10-08 | — | — | EP | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | claimed |
| CN-105873939-B | Beta-hairpin peptidomimetics as selective elastase inhibitors | 波利弗尔股份公司 | 2021-08-27 | — | — | CN | disclosed |
| CN-105873939-A | Beta-hairpin peptidomimetics as selective elastase inhibitors | 波利弗尔股份公司 | 2016-08-17 | — | — | CN | disclosed |
| US-6136781-A | NOVEL CYCLIC PENTAPEPTIDE OR SALTS EFFECTIVE AS MEDICINES FOR PREVENTING AND CURING SEX HORMONE-DEPENDENT CANCERS, PROSTATOMEGALY, ENDOMETRIOSIS, HYSTEROMYOMA, PUBERTY PRECOX, AMENORRHEAL SYNDROMES, MULTIOCULAR OVARIAN SYNDROMES, ALSO | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| CN-1183104-A | LH-RH receptor antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-05-27 | — | — | CN | disclosed |
| EP-0714909-A1 | Composition for prophylaxis or treatment of pulmonary circulatory diseases | Takeda Chemical Industries, Ltd. (JP) | 1996-06-05 | — | — | EP | disclosed |
| EP-0655463-A1 | Cyclic hexapeptides having endothelin antagonistic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | HDAC3 2998/4885HDAC1 3298/4885HDAC2 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.